

**Amendments to the Specification:**

Please amend paragraph 0043 of the specification as follows:

**[0001]** Formulations comprising testosterone may utilize natural testosterone or synthetic testosterones that are absorbed transdermally. For instance, methyl testosterone is suitable for use in the present invention. In premenopausal women, the rate of testosterone production is about 300 µg/day. Accordingly, THDS for testosterone delivery should be formulated for delivery deliver of an amount of testosterone to supplement a partial or total deficiency, i.e., up to about 300 µg daily. Likewise, for treatment of testosterone deficiency in males, THDS should be formulated to deliver up to about 3-6 mg daily.